Review
doi: 10.1016/s0889-8588(02)00051-5.
Clinical development of mammalian target of rapamycin inhibitors
Affiliations
- PMID: 12512385
- DOI: 10.1016/s0889-8588(02)00051-5
Item in Clipboard
Review
Clinical development of mammalian target of rapamycin inhibitors
Hematol Oncol Clin North Am.
2002 Oct.
Abstract
Rapamycin and CCI-779 have significant in vitro and in vivo anti-proliferative activity against a broad range of human tumor cell lines, justifying the clinical evaluation of this class of agent in cancer patients. Preliminary results from phase I studies of CCI-779 suggest that the agent is well tolerated and has anti-tumor activity. The challenge to investigators is to efficiently determine what role this class of agent will play in the treatment of cancer patients.
Similar articles
-
Therapeutic potential of target of rapamycin inhibitors.Expert Opin Ther Targets. 2004 Dec;8(6):551-64. doi: 10.1517/14728222.8.6.551. Expert Opin Ther Targets. 2004. PMID: 15584862 Review.
-
Rapamycin's resurrection: a new way to target the cancer cell cycle.J Natl Cancer Inst. 2001 Oct 17;93(20):1517-9. doi: 10.1093/jnci/93.20.1517. J Natl Cancer Inst. 2001. PMID: 11604470 No abstract available.
-
Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway.Anticancer Drugs. 2006 Jun;17(5):487-94. doi: 10.1097/00001813-200606000-00001. Anticancer Drugs. 2006. PMID: 16702804 Review.
-
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.Oncogene. 2000 Dec 27;19(56):6680-6. doi: 10.1038/sj.onc.1204091. Oncogene. 2000. PMID: 11426655 Review.
-
mTOR pathway inhibitors in cancer therapy: moving past rapamycin.Pharmacogenomics. 2010 Sep;11(9):1189-91. doi: 10.2217/pgs.10.113. Pharmacogenomics. 2010. PMID: 20860456 No abstract available.
Cited by
-
Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.J Clin Oncol. 2011 Aug 20;29(24):3278-85. doi: 10.1200/JCO.2010.34.1578. Epub 2011 Jul 25. J Clin Oncol. 2011. PMID: 21788564 Free PMC article. Clinical Trial.
-
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.Gynecol Oncol. 2011 Oct;123(1):19-26. doi: 10.1016/j.ygyno.2011.06.022. Epub 2011 Jul 12. Gynecol Oncol. 2011. PMID: 21752435 Free PMC article. Clinical Trial.
-
A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C).Cancer. 2011 Aug 1;117(15):3468-75. doi: 10.1002/cncr.25928. Epub 2011 Feb 1. Cancer. 2011. PMID: 21287536 Free PMC article. Clinical Trial.
-
Current Understanding on EGFR and Wnt/β-Catenin Signaling in Glioma and Their Possible Crosstalk.Genes Cancer. 2013 Nov;4(11-12):427-46. doi: 10.1177/1947601913503341. Genes Cancer. 2013. PMID: 24386505 Free PMC article. Review.
-
Targeting mTOR in HIV-Negative Classic Kaposi's Sarcoma.Sarcoma. 2008;2008:825093. doi: 10.1155/2008/825093. Sarcoma. 2008. PMID: 18509482 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
